Exhibit 10.42.3
[DURECT LETTERHEAD]
November 22, 2004
BY FACSIMILE AND EXPRESS MAIL
CONFIDENTIAL
Xxxxx X. Xxxxxx
President
Endo Pharmaceuticals Inc.
000 Xxxxxxxx Xxxxx
Xxxxxx Xxxx, XX 00000
Re: Amendment 2 to Development, Commercialization and Supply License Agreement
Dear Xxxxx:
Reference is made to the Development, Commercialization and Supply License
Agreement between Endo Pharmaceuticals Inc. (Endo) and DURECT Corporation
(DURECT) effective November 8, 2002, as amended effective January 28, 2004
(Agreement). Effective on the date written above, Endo and DURECT hereby agree
to amend the Agreement as follows:
1. Amendment to Section 4.6(a). Section 4.6(a) of the Agreement
shall be amended to replace each instance of January 1, 2005
with January 1, 2006.
2. Amendment to Section 4.6(c). Section 4.6(c) of the Agreement
shall be amended to replace each instance of January 1, 2005
with January 1, 2006.
3. Amendment to Section 13.3(e). Section 13.3(e) of the Agreement
shall be amended to replace January 1, 2005 with January 1,
2006 and January 31, 2005 with January 31, 2006.
Except as set forth above, all other terms of the Agreement shall remain the
same. Please sign below to indicate Endos agreement to the foregoing.
Very truly yours,
/S/ XXXXX X. XXXXX
Xxxxx X. Xxxxx
President and CEO
AGREED TO BY ENDO:
By: /S/ XXXXX X. XXXXXX
------------------------
Xxxxx X. Xxxxxx
President
Date: Nov. 22, 2004
